Peripheral Vascular Disease — Clinical Documentation Guide (2026)

🔍 Definition

Peripheral Vascular Disease (PVD) is a broad term encompassing diseases of the blood vessels outside the heart and brain — primarily the arteries and veins of the extremities, but also mesenteric and renal vasculature. In clinical coding practice, PVD most commonly refers to peripheral arterial disease (PAD), a manifestation of systemic atherosclerosis causing occlusion or stenosis of the arteries supplying the limbs. According to the CDC, approximately 6.5 million Americans age 40 and older have PAD.

The spectrum of PVD includes:

• Atherosclerotic PAD — most common; calcified plaque narrows arterial lumens, reducing perfusion. Coded to the highly specific ICD-10-CM I70.2xx–I70.9 subcategories, which require documentation of the vessel type, site, laterality, and severity (claudication → rest pain → ulceration → gangrene).
• Raynaud's phenomenon/syndrome — episodic vasospasm of digital arteries and arterioles; coded I73.00 (without gangrene) or I73.01 (with gangrene).
• Thromboangiitis obliterans (Buerger's disease) — inflammatory, non-atherosclerotic occlusion strongly associated with tobacco use; coded I73.1.
• Arterial embolism and thrombosis — acute occlusion by embolus or thrombus; I74.xx subcategories specify the vessel.
• Diabetic peripheral angiopathy — macrovascular complication of diabetes; always reported with an etiology-manifestation pair (e.g., E11.51 + I73.9 or E11.52 + I73.9 for with gangrene). See ICD-10-CM Official Guidelines.

Accurate severity documentation — specifically the Rutherford or Fontaine classification and the presence of claudication, rest pain, ulceration, or gangrene — is the single most important CDI lever because it drives both ICD-10-CM specificity and HCC risk-adjustment capture under CMS HCC model v28.

🗂️ Alternative Terminology

🩺 Signs & Symptoms

Clinical presentation depends on severity, location, and acuity of arterial insufficiency. The ACC/AHA 2024 Peripheral Vascular Diseases Guideline classifies PAD using the Rutherford and Fontaine systems:

• Asymptomatic PAD (Rutherford 0 / Fontaine I): Reduced ABI (<0.90) without symptoms; detectable on vascular studies. Document as atherosclerosis of extremity without documented symptoms if incidentally found.
• Intermittent claudication (Rutherford 1–3 / Fontaine IIa–IIb): Reproducible muscle cramping/fatigue with exertion, relieved by rest. Calf claudication → femoropopliteal disease; buttock/thigh claudication → aortoiliac (Leriche syndrome). This is the key ICD-10-CM 5th-digit distinction: "with intermittent claudication" subcategory.
• Ischemic rest pain (Rutherford 4 / Fontaine III): Constant burning pain in foot/toes at rest, worse at night, relieved by dependency. ABI typically <0.40. Must be documented to assign "with rest pain" subcategory codes.
• Tissue loss — ulceration (Rutherford 5 / Fontaine IV): Non-healing ischemic ulcers, typically on toes, heel, or distal foot. Distinct from venous stasis ulcers. Requires documentation of laterality and site for full ICD-10-CM specificity.
• Tissue loss — gangrene (Rutherford 6 / Fontaine IV): Dry or wet gangrene; constitutes critical limb-threatening ischemia. Triggers highest HCC weight under v28. Must be explicitly documented.

Additional signs include: diminished or absent peripheral pulses, cool/pale/mottled extremity, dependent rubor, atrophic skin changes, hair loss on dorsum of foot, delayed capillary refill, tissue necrosis, and abnormal ABI (<0.90 diagnostic; <0.40 critical ischemia; >1.30 suggests calcification requiring toe-brachial index). Acute limb ischemia presents with the classic "6 P's."

🧭 Differential Diagnosis

📋 Clinical Indicators for Coders/CDI

🦴 Anatomy & Pathophysiology

The peripheral arterial system supplying the lower extremities consists of a hierarchical tree: the abdominal aorta bifurcates into the common iliac arteries (external and internal branches), which become the common femoral artery at the inguinal ligament. The common femoral divides into the superficial femoral artery (SFA) (most commonly stenosed in femoropopliteal PAD) and the deep femoral (profunda femoris). The SFA becomes the popliteal artery behind the knee, which trifurcates into the anterior tibial, posterior tibial, and peroneal arteries (tibial/peroneal disease = infrapopliteal or "below-the-knee" PAD).

Atherosclerosis is the dominant pathophysiology: lipid-laden macrophages accumulate in the intima, forming foam cells and fibrous plaques. Progressive calcification, plaque rupture, and superimposed thrombosis reduce luminal diameter and distal perfusion pressure. When demand (exertion) exceeds limited supply, ischemic metabolite accumulation causes claudication. At rest pain stage, resting perfusion is inadequate; at gangrene stage, tissue necrosis is irreversible.

In Raynaud's phenomenon, exaggerated vasospasm of digital arterioles — mediated by abnormal sympathetic and endothelial signaling — causes episodic triphasic color change. Secondary Raynaud's (associated with scleroderma, lupus, or other connective tissue disease) carries higher risk of digital ischemia and gangrene (I73.01).

In Buerger's disease (I73.1), transmural inflammatory infiltration of medium and small vessels — with skip lesions, giant cells, and organizing thrombus — results in distal limb ischemia distinct from atherosclerosis. Tobacco exposure is pathogenic; cessation is mandatory for disease control. According to NCBI StatPearls, Buerger's disease affects upper and lower extremity vessels and can cause superficial thrombophlebitis.

Acute limb ischemia (I74.xx) results from sudden thromboembolism (often cardiac origin in atrial fibrillation) or in-situ thrombosis on a pre-existing plaque. Absent collateral circulation leads to rapid ischemic injury within 4–6 hours, making it a surgical emergency.

💊 Medication Impact / Treatment

Pharmacologic management of PVD directly influences coding by establishing diagnoses, indicating severity, and generating secondary conditions that require documentation:

• Antiplatelet agents (aspirin, clopidogrel/Plavix): Standard therapy for symptomatic PAD; dual antiplatelet post-revascularization. Document concurrent use for drug reconciliation.
• Statins (atorvastatin, rosuvastatin): Mandatory regardless of LDL level in PAD per AHA/ACC 2024 guidelines; document hyperlipidemia if present.
• ACE inhibitors / ARBs: Reduce cardiovascular events in PAD; also treat co-existing HTN — ensure both conditions are coded.
• Cilostazol (Pletal): Phosphodiesterase-3 inhibitor indicated for intermittent claudication (Rutherford 1–3); its use supports documentation of claudication severity and supports I70.2x1 coding.
• Vorapaxar (Zontivity): PAR-1 antagonist for secondary risk reduction in PAD; confirms PAD diagnosis.
• Rivaroxaban (low-dose) + aspirin: The COMPASS regimen for symptomatic PAD; indicates high-risk atherosclerotic disease.
• Prostaglandins (IV iloprost): Used in critical limb ischemia, Buerger's disease, and severe Raynaud's; suggests advanced disease severity.
• Thrombolytics (tPA, urokinase): Used in acute limb ischemia (I74.xx); supports acute coding with high urgency.
• Calcium channel blockers (nifedipine, amlodipine): First-line for Raynaud's syndrome (I73.00/I73.01).
• Pentoxifylline: Rheologic agent for claudication; older use, now less preferred over cilostazol.

Documentation of wound care medications (silver sulfadiazine, becaplermin/Regranex for ischemic ulcers) supports tissue loss coding. Antibiotics for superinfected ischemic wounds trigger additional infection codes (confirm whether cellulitis or osteomyelitis is present — both are separately reportable).

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides